QUOTE AND NEWS
Benzinga  Mar 13  Comment 
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex...
SeekingAlpha  Mar 11  Comment 
Codexis, Inc. (CDXS) Q4 2013 Earnings Conference Call March 11, 2014 04:30 PM ET Executives Doug Sheehy - EVP and CAO John Nicols - President and CEO David O'Toole - SVP and CFO Analysts Presentation ...
StreetInsider.com  Mar 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Codexis%2C+Inc.+%28CDXS%29+Misses+Q4+EPS+by+5c/9270496.html for the full story.
SeekingAlpha  Dec 11  Comment 
ByBrendan O'Boyle: Enzymes are large biological molecules responsible for thousands of metabolic processes that sustain life. These catalysts are optimized through a lengthy period of evolution to accomplish amazingly intricate reactions....
Biomass Magazine  Nov 21  Comment 
Biocatalyst producer Codexis Inc. recently released its financial results for the third quarter of 2013, reporting that it will immediately begin to wind down its CodeXyme cellulase enzyme program for the production of cellulosic sugars.
StreetInsider.com  Nov 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Codexis%2C+Inc.+%28CDXS%29+Tops+Q3+EPS+by+7c%2C+Lowers+FY+Rev+Guidance/8876291.html for the full story.
StreetInsider.com  Aug 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Codexis%2C+Inc.+%28CDXS%29+Misses+Q2+EPS+by+5c/8587870.html for the full story.
Benzinga  Aug 5  Comment 
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced that the company has rescheduled the release of its second quarter financial results due to matters described in...
Benzinga  Aug 5  Comment 
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced that the company has received notice from Dyadic International, Inc. alleging that Codexis is in breach under a...




 
TOP CONTRIBUTORS

Codexis (CDXS) (NASDAQ:CDXS) develops biocatalysts for manufacturing purposes in the pharmaceutical and biofuels industries. Biocatalysts are enzymes or microbes that stimulate or accelerate the chemical reaction. Many manufacturers have relied on naturally occurring biocatalysts, which has its inherent limitations, therefore Codexis provides biocatalysts to allow manufacturers to use them at anytime. The biocatatlysts can improve the manufacturing and commercialization processes for the pharmaceutical industry. In the biofuels industry, it uses biocatalysts to convert biomass into biofuels. [1]

The biocatalyst has specific advantages. Most chemical compounds for manufacturing cannot operate at room temperature, and biocatalyst uses simpler machinery. However there are limitations. Biocatalysts have not been stable enough to be used in industrial setings, therefore it is harder to scale and commercialize the product. Thus, there have been researchers attempting to use biotechnology to alter the genes in the biocatalysts, however there has not be any success to date. [1]

The company's initial public offering of stock filed on the NASDAQ exchange on 29 December 2009. The proposed offer price range is $13.00-$15.00. The company is offering 6.0 million shares and raising $84 million. [1]

For FY2009 with year ended 31 December 2009, the company reported $82.9 million in total revenue, up 64.2% from $50.5 million in total revenue for FY2008. Furthermore, the company had a net loss of $20.3 million in FY2009, an increase from a net loss of $45.1 million in FY2008. The revenues are distributed with 22% in product, 76% in related party collaborative R&D, 2% in collaborative R&D, and the rest in government grants. [1]

References

  1. 1.0 1.1 1.2 1.3 Codexis S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki